AI-Powered ECG could catch hidden heart disease early

NCT ID NCT06978660

Recruiting now Diagnosis Sponsor: Idoven 1903 S.L. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times

Summary

This study is testing a cloud-based AI platform called Willem that analyzes electrocardiogram (ECG) data to detect Transthyretin cardiac amyloidosis (ATTR-CA), a rare and serious heart condition. Researchers will compare ECGs from 2000 adults—some with confirmed ATTR-CA and some without—to see how accurately the AI can tell them apart. The goal is to improve early diagnosis, which can lead to better treatment outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN CARDIAC AMYLOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

wild type ATTR amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRANSTHYRETIN CARDIAC AMYLOIDOSIS

Contacts and locations

Locations

Centre Hospitalier Universitaire de Toulouse
RECRUITING

Toulouse, 31300, France
Hospital Universitario Donostia
COMPLETED

San Sebastián, Guipúzcoa, 20014, Spain
Hospital Universitario Juan Ramón Jiménez
COMPLETED

Huelva, Huelva, 21005, Spain
Hospital Universitario Son Llàtzer
RECRUITING

Palma de Mallorca, Balearic Islands, 07198, Spain
Northwestern University
COMPLETED

Evanston, Illinois, 60208, United States
Queen Elizabeth University Hospital, Univeisity of Glasgow
RECRUITING

Glasgow, G51 4TF, United Kingdom
TUM Klinikum Deutsches Herzzentrum
NOT_YET_RECRUITING

München, 80636, Germany
Universitätsklinikum Bonn
COMPLETED

Bonn, 53127, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.